Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

David Fabregat-Safont

2 papers in the library · 22 citations · publishing 2023

Papers

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie December 31, 2023 Francisco Madrid-Gambin, David Fabregat-Safont, Alex Gomez-Gomez et al. 12 citations

Psychedelics like LSD, mescaline, DMT, ayahuasca, 5-methoxy-DMT, and psilocybin induce altered states of consciousness and are being studied for treating mental health disorders. This review examines metabolic and metabolomics studies in humans after administration of these drugs. The main metabolites for classical psychedelics have been robustly established, but the metabolic alterations they induce need further exploration. Integrating metabolomics with pharmacokinetics may help understand the therapeutic role of psychedelics by revealing molecular interactions with multiple targets.

Characterization of the recently detected cathinone N-cyclohexyl butylone: From structure elucidation to in silico supported pharmacological/toxicological considerations

Microchemical Journal February 28, 2023 María Mata-Pesquera, David Fabregat-Safont, Cristina Gil et al. 10 citations

A recently detected synthetic cathinone, N-cyclohexyl butylone, was characterized using gas chromatography–mass spectrometry, liquid chromatography–high-resolution mass spectrometry, nuclear magnetic resonance, and Fourier-transform infrared spectroscopy. The compound's elemental composition and molecular structure were determined from accurate-mass ions and two-dimensional NMR experiments. In silico predictions suggest that N-cyclohexyl butylone likely produces stimulant effects similar to MDMA. This work provides a complete analytical profile for a new psychoactive substance that has appeared in European drug markets.